Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Raphamin, Placebo.
- Who it may be relevant to
- Registry conditions: Acute Respiratory Viral Infection. Basic parameters: 3 years — 12 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Russia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Respiratory Viral Infection in Children Aged 3-12 Years
Overview
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.
Detailed description
Design: a multicenter, double-blind, placebo-controlled, randomized, parallel-group clinical trial.
The trial will enroll outpatients of either gender aged 3 to 12 years with clinical manifestations of acute respiratory viral infection (ARVI) within the first 24 hours after the disease onset. Patient enrollment will be conducted in 2 stages during the seasonal incidence of ARVI. First, children aged 6-12 years will be enrolled in the trial. Once the required number of patients is reached, an "unblinded" interim analysis with the primary efficacy endpoint assessment and safety analysis will be performed. Based on the data from the unblinded interim analysis, a decision will be made whether the age range of enrollment can be expanded from 3 to 12 years. Patient enrollment will not be stopped until the results of the "unblinded" interim analysis are available.
After the parent/adopter signs the information sheet and informed consent form for the patient's parents/adopters to participate in the clinical trial, the medical history will be collected, thermometry, objective examination, laboratory tests will be performed, and concomitant therapy will be recorded. The severity of ARVI symptoms will be assessed using a 4-point scale.
The nasopharyngeal swabs for PCR diagnosis and verification of respiratory viruses will be performed prior to therapy to confirm the viral etiology of ARVI.
If a patient meets all inclusion criteria and does not have any exclusion criteria, at Visit 1 (Day 1), they will be randomized into one of two groups: Group 1 patients will receive Raphamin according to the dosage regimen for 5 days; Group 2 patients will receive Placebo using the Raphamin dosage regimen for 5 days.
The trial will utilize an electronic patient diary (EPD) where the patient will make daily records of morning and evening axillary body temperature (measured with a classic mercury-free thermometer) and symptoms of the disease (ARVI Symptom Severity Score). In addition, antipyretic dosing (if applicable) as well as any possible worsening of the patient's condition (if applicable, to assess safety / to record adverse events) will also be recorded in the patient diary. The investigator will instruct the parent/adopter on how to complete the diary. At Visit 1, the parent/adopter together with the physician will record the severity of ARVI symptoms and body temperature in the diary.
The patient will be observed for 14 days (screening, randomization - up to 1 day, treatment - 5 days, follow-up - up to 2 days; deferred "phone visit" - day 14).
During the treatment and follow-up period, patients/physicians will pay 3 visits, and the fourth "phone visit" will be scheduled additionally: 1) physician/patient visits - on days 1, 5 and 7 (Visits 1, 2 and 3) - at the health center or at home; 2) a phone "visit" by the physician (Visit 4) - on day 14.
During Visits 2 and 3, the physician will perform objective examination, record changes in the disease symptoms, concomitant therapy, and monitor the completion of the diary. During Visit 3, compliance will be assessed and laboratory tests will be performed.
A phone "visit" will be performed to interview the parent/adopter about the patient's condition, presence/absence of secondary bacterial/viral complications, and use of antibiotics.
Symptomatic therapy and therapy for concomitant diseases will be permitted during the trial except for the drugs listed under "Prohibited Concomitant Treatment".
Interventions
- Drug Raphamin
Tablet for oral use. - Drug Placebo
Tablet for oral use.
Primary outcome measures
- Time to resolution of ARVI symptoms (PCR-confirmed) [Time frame: 14 days]
Secondary outcome measures (12)
- ARVI severity (clinically diagnosed, including PCR-confirmed) [Time frame: From day 1 to day 6]
- Percentage of patients with resolution of ARVI symptoms [Time frame: 14 days]
- Time to resolution of ARVI symptoms [Time frame: 14 days]
- Percentage of patients with resolution of ARVI symptoms (PCR-confirmed) [Time frame: 14 days]
- Dosing frequency of antipyretics [Time frame: From day 1 to day 3]
- Percentage of patients with worsening of the disease [Time frame: From day 4 to day 14]
- Number of Participants With Adverse Events (AEs) [Time frame: From day 1 to day 6]
- Severity of AEs [Time frame: From day 1 to day 6]
- Causal Relationship of AEs to the Sudy Drug [Time frame: From day 1 to day 6]
- Outcome of AEs [Time frame: From day 1 to day 6]
- Changes in Vital Signs (Blood Pressure) measured in mm Hg [Time frame: On Visit 1 (day 1), Visit 2 (day 5) and Visit 3 (day 7)]
- Changes in Vital Signs (Heart Rate) [Time frame: On Visit 1 (day 1), Visit 2 (day 5) and Visit 3 (day 7)]
Eligibility criteria
Inclusion criteria
- Children of either gender aged 3 to12 years .
- Diagnosis of ARVI based on the medical examination: axillary temperature ≥37.8°C at the time of examination + total severity of general symptom score ≥4 points, nasal/throat/chest symptoms ≥2 points (ARVI Symptom Severity Score).
- 24 hours from the ARVI onset .
- Availability of a patient information sheet and an informed consent form for the patient's parents/adopters for patient participation in the clinical trial signed by one parent/adopter of the patient.
Exclusion criteria
- Clinical symptoms of severe influenza/ARVI requiring hospitalization.
- Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) requiring the administration of antibiotics from the first day of disease.
- Suspected early manifestations of diseases that have onset symptoms similar to those of ARVI (other infectious diseases, influenza-like syndrome at the onset of systemic connective tissue diseases and other pathologies).
- Patients who require administration of antiviral medications that are prohibited for use in this trial.
- History or prior diagnosis of primary and secondary immunodeficiency.
- History/suspicion of oncology of any localization (except for benign neoplasms).
- Exacerbation or decompensation of chronic diseases (diabetes mellitus, cerebral palsy, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, malformations of the respiratory and ENT organs, etc.) affecting the patient's ability to participate in the clinical trial.
- Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.
- Allergy/hypersensitivity to any component of the medicines used in the treatment.
- Use of medications listed under "Prohibited Concomitant Treatment" within 2 weeks prior to inclusion in the trial.
- Patients whose parents/adopters, from the investigator's point of view, will not comply with the observation requirements during the trial or follow the procedure for taking the test drugs.
- History of mental illness of the patient (except for attention deficit hyperactivity disorder), parents/adopters of the patient.
- Participation in other clinical trials within 3 months prior to inclusion in this trial.
- A patient's parent/adopter is related to any of the on-site research personnel directly involved in the trial, or is the immediate family member of the investigator. 'Immediate family members' mean spouses, parents, children, or siblings, whether related or adopted.
- The patient's parent/adopter is employed by OOO "NPF "MATERIA MEDICA HOLDING", i.e., is an employee of the company, a temporary contract employee, or a designated official responsible for conducting the trial or their immediate family member.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Russia · 35 centers
- Gatchina Clinical Interdistrict Hospital — Gatchina
- Kazan State Medical University/Department of Hospital Pediatrics — Kazan'
- LLC "MedLight" — Kazan'
- Regional Clinical Hospital # 2 — Krasnodar
- Specialized Clinical Infectious Diseases Hospital — Krasnodar
- Central Research Institute of Epidemiology/Clinical Department of Infectious Pathology — Moscow
- Morozovskaya Children's City Clinical Hospital of the Moscow City Health Department — Moscow
- First Moscow State Medical University named after I.M. Sechenov/Department of Childhood Di — Moscow
- … and 27 more centers
Identifiers
NCT: NCT06715891 · MMH-407-010